Drug intelligence / Profile preview

AT3022

Development stage: Unknown
Lead developer: Nitto
Modality: Small Molecules
Administration: Transdermal

Overview

AT3022 is a transdermal patch formulation of fentanyl citrate developed by Altea Therapeutics for the management of moderate to severe chronic pain. The product utilizes the proprietary PassPort™ Transdermal System, which employs thermal microporation to create microscopic channels in the stratum corneum, facilitating the delivery of water-soluble molecules like fentanyl citrate across the skin. Unlike traditional fentanyl patches that deliver the highly lipid-soluble base form of the drug, AT3022 is designed to provide rapid onset and controlled delivery of the salt form, potentially offering a safer and more efficacious profile for pain management. The program entered Phase I clinical trials in 2008.

Other names: fentanyl citrate transdermal patchPassPort fentanyl

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on AT3022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT3022.

Explore the full profile